Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study evaluating 2-Deoxy-D-glucose (2-DG)

Next Previous
Search
Trial Profile

A phase 2 study evaluating 2-Deoxy-D-glucose (2-DG)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 2-deoxy-D-glucose (Primary)
  • Indications Nose disorders; Rhinovirus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Apr 2024 According to a G.ST Antivirals media release, Planned number of volunteers to be enrolled in this trial is 128.
    • 09 Apr 2024 According to a G.ST Antivirals media release, company announced the appointment of Ronald Bruce Turner, MD, as new Chief Medical Officer (CMO).
    • 09 Apr 2024 According to a G.ST Antivirals media release, first subject was dosed on April 2nd, 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top